COVID-19 Prognosis in Patients With/Without a History of ACEI/ARB Consumption

Document Type : Original Article

Authors

1 Department of Cardiology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

2 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

3 Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

4 Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

5 Department of Radiology and Health Research Center Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

6 Biostatistics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.

7 Faculty of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, IR Iran.

Abstract

Background: Hypertension is a critical risk factor in increasing the mortality rate of COVID-19 inpatients. This association can be confounded by a history of consuming some angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs).
Objective: This study aimed to assess the COVID-19 prognosis in patients with/without a history of taking ACEIs and ARBs.
 
Methods: This single-center, prospective, observational study was performed on 345 patients with COVID-19 hospitalized in Baqiyatallah Hospital. The patients were categorized into 2 groups: with a history of ACEI/ARB consumption (the case group, n=115) and without such a history (the control group, n=230).
 
Results: After the exclusion of some patients, the COVID-19 prognosis of 294 patients (ncontrol =184, ncase=110, 53% female) at a mean age of 64±9.7 years was evaluated. Unequal variables were adjusted between the case and control groups, and the results showed no significant differences in oxygen saturation, the computed tomography scan score, the erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase, D-dimer, the white blood cell count, lymphocytes, hemoglobin, platelets, and mortality between the 2 groups. However, a significant difference in the average length of hospital stay was found between the control (6.55±0.56 d) and case (8.53±0.55 d) groups (P=0.013).
 
Conclusions: The dosage adjustments and changes of ACEIs and ARBs are not recommended due to increased referrals to health centers involved with the COVID-19 risk. The prognosis, safety, and efficacy of ACEI/ARB consumption should be assessed further in larger studies on middle-aged to old patients with COVID-19. (Iranian Heart Journal 2022; 23(1): 129-139)

Keywords


  1. Rajan R, Al Jarallah M, Dashti R. Cardiovascular complications of novel Wuhan Coronavirus COVID ndash: A 2020 update. J Cardiol Curr Res. 2020;13(13), 28. doi: 10.15406/jccr.2020.13.00468
  2. Mirzadeh M, Khedmat L. Pregnant women in the exposure to COVID-19 infection outbreak: the unseen risk factors and preventive healthcare patterns. J Matern-Fetal Neonatal Med. 2020; doi: 10.1080/14767058.2020.1749257.
  3. Khedmat L. New coronavirus (2019-nCoV): An insight toward preventive actions and natural medicine. Int J Travel Med Glob Health. 2020;8(1):44-5. doi: 10.34172/ijtmgh.2020.07.
  4. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5.
  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
  6. Amiri P, Vahedi-Notash G, Naseri P, Khalili D, Nazari SS, Mehrabi Y, et al. National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007–2011). Biol Sex Differ. 2019;10(1):15. doi: 10.1186/s13293-019-0230-1.
  7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; doi:10.1016/S0140-6736(20)30566-3.
  8. Kloor D, Osswald H. S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. Trends Pharmacol Sci. 2004;25(6):294-7. doi: 10.1016/j.tips.2004.04.004.
  9. Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr. 2020;8:206. doi: 10.3389/fped.2020.00206.
  10. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?. JAMA. 2020; 323(18):1769-70. doi:10.1001/jama.2020.4812
  11. Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Chin J Tuberc Respir Dis. 2020;43:E014. doi:10.3760/cma.j.issn.1001-0939.2020.0014
  12. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Rev Cardiol. 2020;17(5):259-60. doi: 10.1038/s41569-020-0360-5
  13. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383(1):45-51. doi: 10.1042/BJ20040634
  14. American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 20, 2020.https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp
  15. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. Accessed March 20,2020.https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
  16. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Mil Med Res. 2020;7(1):article no.11. doi: 10.1186/s40779-020-00240-0.
  17. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4.
  18. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020:200370. doi: 10.1148/radiol.2020200370.
  19. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Res. 2020; 126:1671–81. doi: 10.1161/CIRCRESAHA.120.317134
  20. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020; 382:2441-8. doi: 10.1056/NEJMoa2008975.
  21. Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clin Exp Hypertens. 2020; 42(7):656-660.doi:10.1080/10641963.2020.1764018
  22. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr: Clin Res Rev. 2020; 14(4):283-7. doi: 10.1016/j.dsx.2020.03.016
  23. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ.Res. 2020; 126:1671-81. doi: 10.1161/CIRCRESAHA.120.317134
  24. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microb Infect. 2020;9(1):757-60. doi: 10.1080/22221751.2020.1746200
  25. Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL, et al. Beta Blocker and angiotensin-converting enzyme Inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation.2004;11(3):173-180. doi: 10.1159/000076766
  26. Andersen LB, Przybyl L, Haase N, von Versen‐Höynck F, Qadri F, Jørgensen JS, et al. Vitamin D depletion aggravates hypertension and target‐organ damage. J Am Heart Assoc. 2015; 4(2):e001417. doi: 10.1161/JAHA.114.001417.
  27. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am JRespir CritCare Med. 2020;201(11):1380-8.doi:10.1164/rccm.202002-0445